AK129 Combination Therapy for Advanced Solid Tumors

This trial is testing AK129 — a new immunotherapy drug — in combination with other treatments for patients with advanced lung cancer (NSCLC), head and neck cancer (HNSCC), or colorectal cancer that has progressed after standard therapies including platinum chemotherapy and PD-1/PD-L1 immunotherapy. **You may be eligible if...** - You are aged 18–75 - You have confirmed advanced NSCLC, HNSCC, or colorectal cancer - Your cancer has progressed during or after platinum-based chemotherapy and a PD-1/PD-L1 immunotherapy drug - Your performance status is ECOG 0–1 and your life expectancy is more than 3 months - You have measurable disease on scans **You may NOT be eligible if...** - You have not previously received both platinum chemotherapy and immunotherapy - You have active brain metastases or untreated CNS involvement - You have severe autoimmune disease or organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.